Interleukin Genetics — IPO Roadshow (June 2016)
28 slides from Interleukin Genetics's IPO roadshow presentation, Jun 7, 2016
Slide 1: Interleukin Genetics Investor Overview June 2016
I N T E R L E U K I N G E N E T I C S Page 1 Transforming Inflammation Management Making Genetic Insights Actionable Interleukin Genetics Investor Overview June 2016 Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. 333 - 211361 Dated June 7, 2016
Slide 2: Safe Harbor
I N T E R L E U K I N G E N E T I C S Page 2 Safe Harbor This presentation may contain forward - looking statements. These statements reflect our current views with respect to future events and actual results could differ materially from those projected in the forward - looking statements. Factors t
Slide 3: About This Free Writing Prospectus
I N T E R L E U K I N G E N E T I C S Page 3 About This Free Writing Prospectus • This presentation highlights basic information about us and the offering. Because it is a summary that has been prepared solely for informational purposes, it does not contain all of the information that you should con
Slide 4: Offering Summary
I N T E R L E U K I N G E N E T I C S Page 4 Offering Summary • Expected to fund Interleukin into the future ‒ Historical (2015 - Q1 2016) burn rate ~ $550 - 600k per month ‒ Expect to move toward profitability as revenue ramps up • Use of Proceeds ‒ Expand commercial capabilities; Sales team, Marke
Slide 5: Corporate Snapshot
I N T E R L E U K I N G E N E T I C S Page 5 Corporate Snapshot • Digital health platform to drive actionable insights • State - of - the art capabilities, with a CLIA - certified laboratory • Boston metro area headquarters • Founded in 1999; 17 employees • OTCQB: ILIU • Market Capitalization: $25.9
Slide 6: Interleukin Genetics Value Drivers
I N T E R L E U K I N G E N E T I C S Page 6 Interleukin Genetics Value Drivers Making Genetic Insights Actionable Focused Strategy Actionable Solutions Leaders in IL - 1 Biology Compelling Value Important Clinical Need • Turnkey program to manage inflammation through targeted dental care • Leveragi
Slide 7: Accomplished Leadership Team
I N T E R L E U K I N G E N E T I C S Page 7 Accomplished Leadership Team Mark Carbeau Chief Executive Officer Ken Kornman , DDS, PhD President and Chief Scientific Officer Steve DiPalma Chief Financial Officer Joe Zack Chief Commercial Officer Lynn Doucette, PhD Vice President Development and Clini
Slide 8: Inflammation: A Driving Force in Chronic Diseases
I N T E R L E U K I N G E N E T I C S Page 8 Inflammation: A Driving Force in Chronic Diseases Accounts for ~83% of Healthcare Costs in U.S. INFLAMMATION Cardiovascular Disease Adverse Pregnancy Outcomes Metabolic Syndrome Diabetes Rheumatoid Arthritis Chronic Kidney Disease Obesity Chronic Periodon
Slide 9: Interleukin - Regulates Inflammatory Cascades
I N T E R L E U K I N G E N E T I C S Page 9 Interleukin - 1 Regulates Inflammatory Cascades Bacterial pathogens or injury challenges to any tissue Immediate response genes Activation of preformed mediators: Lipids, complement, histamine, kinins , etc 2nd wave cytokines IL - 6 IL - 10 IL - 8 Inflamm
Slide 10: Managing Inflammation Makes a Difference
I N T E R L E U K I N G E N E T I C S Page 10 Managing Inflammation Makes a Difference Impacts Onset Impacts Severity Impacts Progression Increased systemic inflammatory burden contributes to the prevalence of multiple chronic diseases: +40% Diabetes +40% Stroke +30% Coronary artery disease for Card
Slide 11: Ticking Time Bombs: Under-diagnosed and Under-managed Diseases
I N T E R L E U K I N G E N E T I C S Page 11 Ticking Time Bombs Under - diagnosed and Under - managed Inflammatory - Mediated Diseases Inflammatory Disease US Prevalence (millions) Sources: JAMA (2014), CDC (2010 & 2013), National Statistical Report (2014) ` 0 20 40 60 80 100 120 140 Prevalance Und
Slide 12: Turnkey Program Targets Chronic Inflammation and Drives Behavioral Change
I N T E R L E U K I N G E N E T I C S Page 12 Identify high - risk patients via simple cheek swab Communicate results to patients through healthcare professional (HCP) Provide tools to educate high - risk patients and HCPs who manage their care Educating Your Patients: Genetic Risk for Chronic Perio
Slide 13: Unexpected Connection, Surprising Impact
I N T E R L E U K I N G E N E T I C S Page 13 • Dental cleanings of patients with gingivitis reduce blood CRP 1 level by 69% • Intensive dental treatment of moderate to severe periodontitis reduces CRP by 20% to 39% in three independent studies • In patients with Type 2 diabetes, treatment of period
Slide 14: Targeted Dental Care Decreases Costs
I N T E R L E U K I N G E N E T I C S Page 14 Targeted Dental Care Decreases Costs A Powerful Leverage Point Potential Health Plan Savings of up to 8%* Investment (per person) $200 $80 - $160 Identify Inflammation Risk (one time) Dental Cleanings (annually) *Mean savings over 4 years comparing appro
Slide 15: Digital Health Engagement Tools To Ensure Impact
I N T E R L E U K I N G E N E T I C S Page 15 Digital Health Engagement Tools To Ensure Impact Build awareness and drive test adoption Objective: Deliver Health Info & Appointment Reminders Tools: At - risk Employees Employer Dental Office Audience Communication Objectives and Tools Impact • Impleme
Slide 16: Large Market Potential with Attractive Margins
I N T E R L E U K I N G E N E T I C S Page 16 Large Market Potential with Attractive Margins Executing on Base Business Significant market potential… 170MM Adults with Dental Coverage 45MM Employed by Large Companies Addressable Market Target Market …with attractive returns Robust gross margins: 80
Slide 17: Large Employers Offer Immediate Access
I N T E R L E U K I N G E N E T I C S Page 17 Large Employers Offer Immediate Access Executing Sales Strategy To Provide Early Traction Potential Revenue Yield Illustration 30,000 Eligible 25,000 employees x 1.2 factor (adult dependents) 9,000 Tested 30% potential conversion to testing $200 Revenue
Slide 18: Carriers Accelerate Adoption
I N T E R L E U K I N G E N E T I C S Page 18 Carriers Accelerate Adoption Longer Sales Cycle; Larger Opportunity Potential Revenue Yield Illustration 10,000,000 Total Covered Lives 25% Carrier targets sales efforts to one quarter of accounts 30% Penetration into Targeted accounts 30% Potential test
Slide 19: Leveraging Data Assets and Patient Relationships
I N T E R L E U K I N G E N E T I C S Page 19 Leveraging Data Assets and Patient Relationships Diabetes Disease Management a Smart Starting Point • Patient relationship and access • Patient behavioral insights • Genetic risk stratification • Oral health status • Dental care team access Diabetes a st
Slide 20: Leveraging Our IL-Genetics Platform
I N T E R L E U K I N G E N E T I C S Page 20 Leveraging Our IL - 1 Genetics Platform Potential To Facilitate Precision Medicine in Inflammation Opportunities to expand IG impact on clinical management of inflammation in the long term IL - 1 Platform Multiple Clinical Indications Cardiovascular Dise
Slide 21: Firms Actively Developing IL-1 Blocking Drugs
I N T E R L E U K I N G E N E T I C S Page 21 Multiple indications demonstrating large unmet need • Many in late stage development • Several address large diseases with high unmet need Cross section of large and small size companies Firms Actively Developing IL - 1 Blocking Drugs Expensive Treatment
Slide 22: Possible Expansion of Base Business
I N T E R L E U K I N G E N E T I C S Page 22 ` ` ` Possible Expansion of Base Business Vision for Future Growth Leveraging Genetic and Digital Health Platforms Key Genetics Platform Digital Health Platform Both Platforms Engagement Subscriptions Disease Management Partnering Clinical Testing/Compan
Slide 23: Broad IP Protects Tests and IL-Pathway
I N T E R L E U K I N G E N E T I C S Page 23 Broad IP Protects Tests and IL - 1 Pathway Patent Family Patents Applications US Outside US US Outside US IL - 1 4 Protected through 2027 8 Protected through 2023 1 1 Periodontitis 1 Protected through 2033 3 1 9 Cardiovascular 2 2 Osteoarthritis 2 4 2 4
Slide 24: Goals and Milestones for 2016
I N T E R L E U K I N G E N E T I C S Page 24 Goals and Milestones for 2016 x Initial contracts with employers • First pilot with insurance carrier • Population health initiative with government entity (ex - US) x Add key commercial staff - Chief Commercial Officer, National Account Directors, Marke
Slide 25: Interleukin Genetics Value Drivers
I N T E R L E U K I N G E N E T I C S Page 25 Interleukin Genetics Value Drivers Making Genetic Insights Actionable Focused Strategy Actionable Solutions Leaders in IL - 1 Biology Compelling Value Important Clinical Need • Turnkey program to manage inflammation through targeted dental care • Leverag
Slide 26: Appendix
I N T E R L E U K I N G E N E T I C S Page 26 Appendix
Slide 27: Scientific Advisory Board
I N T E R L E U K I N G E N E T I C S Page 27 Scientific Advisory Board • Former Chairman (through Dec 2014) of the Medicines and Healthcare Products Regulatory Agency --- UK equivalent of U.S. FDA • Principal, St Hilda’s College, Oxford University UK • Former Florey Professor of Molecular Medicine,
Slide 28: Clinical Advisory Board
I N T E R L E U K I N G E N E T I C S Page 28 Clinical Advisory Board • Principal, St Hilda’s College, Oxford University UK and Former Florey Professor of Molecular Medicine, University of Sheffield • 300+ publications Sir Gordon Duff MD, BM, BCh , FRCP, PhD, Fmed Sci Iain Chapple, PhD. BDS. FDSRCPS